MedTrace Logo

Metformin and Congenital Nephrogenic Diabetes Insipidus

NCT02460354 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2018-07-17

No results posted yet for this study

Summary

The purpose of this study is to determine whether metformin can increase urine concentration (osmolality) and decrease the amount of urine in patients with congenital nephrogenic diabetes insipidus (NDI).

Conditions

  • Diabetes Insipidus

Interventions

DRUG

Metformin

Metformin 500 mg pill dispensed once orally

Sponsors & Collaborators

  • Emory University

    lead OTHER

Principal Investigators

  • Larry Greenbaum, MD, PhD · Emory University

  • Titilayo Ilori, MD · Emory University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2017-06-30
Completion
2017-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02460354 on ClinicalTrials.gov